Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant

Shane Atwell, Christie G. Brouillette, Kris Conners, Spencer Emtage, Tarun Gheyi, William B Guggino, Jorg Hendle, John F. Hunt, Hal A. Lewis, Frances Lu, Irina I. Protasevich, Logan A. Rodgers, Rich Romero, Stephen R. Wasserman, Patricia C. Weber, Diana Wetmore, Feiyu F. Zhang, Xun Zhao

Research output: Contribution to journalArticle

Abstract

Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(Δ405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7- resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.

Original languageEnglish (US)
Pages (from-to)375-384
Number of pages10
JournalProtein Engineering, Design and Selection
Volume23
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Adenosinetriphosphate
Nucleotides
Monomers
Proteins
Conformations
Adenosine Triphosphate
Excipients
Association reactions
X rays
X-Rays
Mutation
Experiments

Keywords

  • ΔF508
  • ABC transporter
  • CFTR
  • NBD1
  • Regulatory insert

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Bioengineering
  • Molecular Biology

Cite this

Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. / Atwell, Shane; Brouillette, Christie G.; Conners, Kris; Emtage, Spencer; Gheyi, Tarun; Guggino, William B; Hendle, Jorg; Hunt, John F.; Lewis, Hal A.; Lu, Frances; Protasevich, Irina I.; Rodgers, Logan A.; Romero, Rich; Wasserman, Stephen R.; Weber, Patricia C.; Wetmore, Diana; Zhang, Feiyu F.; Zhao, Xun.

In: Protein Engineering, Design and Selection, Vol. 23, No. 5, 05.2010, p. 375-384.

Research output: Contribution to journalArticle

Atwell, S, Brouillette, CG, Conners, K, Emtage, S, Gheyi, T, Guggino, WB, Hendle, J, Hunt, JF, Lewis, HA, Lu, F, Protasevich, II, Rodgers, LA, Romero, R, Wasserman, SR, Weber, PC, Wetmore, D, Zhang, FF & Zhao, X 2010, 'Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant', Protein Engineering, Design and Selection, vol. 23, no. 5, pp. 375-384. https://doi.org/10.1093/protein/gzq004
Atwell, Shane ; Brouillette, Christie G. ; Conners, Kris ; Emtage, Spencer ; Gheyi, Tarun ; Guggino, William B ; Hendle, Jorg ; Hunt, John F. ; Lewis, Hal A. ; Lu, Frances ; Protasevich, Irina I. ; Rodgers, Logan A. ; Romero, Rich ; Wasserman, Stephen R. ; Weber, Patricia C. ; Wetmore, Diana ; Zhang, Feiyu F. ; Zhao, Xun. / Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. In: Protein Engineering, Design and Selection. 2010 ; Vol. 23, No. 5. pp. 375-384.
@article{e31cecd8c5714d11af4a6b86f7bfb349,
title = "Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant",
abstract = "Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(Δ405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7- resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.",
keywords = "ΔF508, ABC transporter, CFTR, NBD1, Regulatory insert",
author = "Shane Atwell and Brouillette, {Christie G.} and Kris Conners and Spencer Emtage and Tarun Gheyi and Guggino, {William B} and Jorg Hendle and Hunt, {John F.} and Lewis, {Hal A.} and Frances Lu and Protasevich, {Irina I.} and Rodgers, {Logan A.} and Rich Romero and Wasserman, {Stephen R.} and Weber, {Patricia C.} and Diana Wetmore and Zhang, {Feiyu F.} and Xun Zhao",
year = "2010",
month = "5",
doi = "10.1093/protein/gzq004",
language = "English (US)",
volume = "23",
pages = "375--384",
journal = "Protein Engineering, Design and Selection",
issn = "1741-0126",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant

AU - Atwell, Shane

AU - Brouillette, Christie G.

AU - Conners, Kris

AU - Emtage, Spencer

AU - Gheyi, Tarun

AU - Guggino, William B

AU - Hendle, Jorg

AU - Hunt, John F.

AU - Lewis, Hal A.

AU - Lu, Frances

AU - Protasevich, Irina I.

AU - Rodgers, Logan A.

AU - Romero, Rich

AU - Wasserman, Stephen R.

AU - Weber, Patricia C.

AU - Wetmore, Diana

AU - Zhang, Feiyu F.

AU - Zhao, Xun

PY - 2010/5

Y1 - 2010/5

N2 - Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(Δ405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7- resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.

AB - Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(Δ405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7- resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.

KW - ΔF508

KW - ABC transporter

KW - CFTR

KW - NBD1

KW - Regulatory insert

UR - http://www.scopus.com/inward/record.url?scp=77951118320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951118320&partnerID=8YFLogxK

U2 - 10.1093/protein/gzq004

DO - 10.1093/protein/gzq004

M3 - Article

C2 - 20150177

AN - SCOPUS:77951118320

VL - 23

SP - 375

EP - 384

JO - Protein Engineering, Design and Selection

JF - Protein Engineering, Design and Selection

SN - 1741-0126

IS - 5

ER -